Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:
“Julia Rotow gives her take on 1L EGFR options coming out of WCLC25 FLAURA2 presentation weighting in survival advantage (Quantity time) vs Quality of time (osi monotherapy).”
More posts featuring Julia Rotow.
